Cargando…

Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation

BACKGROUND: Casitas B-lineage lymphoma (Cbl or c-Cbl) is a RING ubiquitin ligase that negatively regulates protein tyrosine kinase (PTK) signalling. Phosphorylation of a conserved residue (Tyr371) on the linker helix region (LHR) between the substrate-binding and RING domains is required to ubiquiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Buetow, Lori, Tria, Giancarlo, Ahmed, Syed Feroj, Hock, Andreas, Dou, Hao, Sibbet, Gary J., Svergun, Dmitri I., Huang, Danny T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015263/
https://www.ncbi.nlm.nih.gov/pubmed/27609087
http://dx.doi.org/10.1186/s12915-016-0298-6
_version_ 1782452403850706944
author Buetow, Lori
Tria, Giancarlo
Ahmed, Syed Feroj
Hock, Andreas
Dou, Hao
Sibbet, Gary J.
Svergun, Dmitri I.
Huang, Danny T.
author_facet Buetow, Lori
Tria, Giancarlo
Ahmed, Syed Feroj
Hock, Andreas
Dou, Hao
Sibbet, Gary J.
Svergun, Dmitri I.
Huang, Danny T.
author_sort Buetow, Lori
collection PubMed
description BACKGROUND: Casitas B-lineage lymphoma (Cbl or c-Cbl) is a RING ubiquitin ligase that negatively regulates protein tyrosine kinase (PTK) signalling. Phosphorylation of a conserved residue (Tyr371) on the linker helix region (LHR) between the substrate-binding and RING domains is required to ubiquitinate PTKs, thereby flagging them for degradation. This conserved Tyr is a mutational hotspot in myeloproliferative neoplasms. Previous studies have revealed that select point mutations in Tyr371 can potentiate transformation in cells and mice but not all possible mutations do so. To trigger oncogenic potential, Cbl Tyr371 mutants must perturb the LHR-substrate-binding domain interaction and eliminate PTK ubiquitination. Although structures of native and pTyr371-Cbl are available, they do not reveal how Tyr371 mutations affect Cbl’s conformation. Here, we investigate how Tyr371 mutations affect Cbl’s conformation in solution and how this relates to Cbl’s ability to potentiate transformation in cells. RESULTS: To explore how Tyr371 mutations affect Cbl’s properties, we used surface plasmon resonance to measure Cbl mutant binding affinities for E2 conjugated with ubiquitin (E2–Ub), small angle X-ray scattering studies to investigate Cbl mutant conformation in solution and focus formation assays to assay Cbl mutant transformation potential in cells. Cbl Tyr371 mutants enhance E2–Ub binding and cause Cbl to adopt extended conformations in solution. LHR flexibility, RING domain accessibility and transformation potential are associated with the extent of LHR-substrate-binding domain perturbation affected by the chemical nature of the mutation. More disruptive mutants like Cbl Y371D or Y371S are more extended and the RING domain is more accessible, whereas Cbl Y371F mimics native Cbl in solution. Correspondingly, the only Tyr371 mutants that potentiate transformation in cells are those that perturb the LHR-substrate-binding domain interaction. CONCLUSIONS: c-Cbl’s LHR mutations are only oncogenic when they disrupt the native state and fail to ubiquitinate PTKs. These findings provide new insights into how LHR mutations deregulate c-Cbl. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12915-016-0298-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5015263
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50152632016-09-09 Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation Buetow, Lori Tria, Giancarlo Ahmed, Syed Feroj Hock, Andreas Dou, Hao Sibbet, Gary J. Svergun, Dmitri I. Huang, Danny T. BMC Biol Research Article BACKGROUND: Casitas B-lineage lymphoma (Cbl or c-Cbl) is a RING ubiquitin ligase that negatively regulates protein tyrosine kinase (PTK) signalling. Phosphorylation of a conserved residue (Tyr371) on the linker helix region (LHR) between the substrate-binding and RING domains is required to ubiquitinate PTKs, thereby flagging them for degradation. This conserved Tyr is a mutational hotspot in myeloproliferative neoplasms. Previous studies have revealed that select point mutations in Tyr371 can potentiate transformation in cells and mice but not all possible mutations do so. To trigger oncogenic potential, Cbl Tyr371 mutants must perturb the LHR-substrate-binding domain interaction and eliminate PTK ubiquitination. Although structures of native and pTyr371-Cbl are available, they do not reveal how Tyr371 mutations affect Cbl’s conformation. Here, we investigate how Tyr371 mutations affect Cbl’s conformation in solution and how this relates to Cbl’s ability to potentiate transformation in cells. RESULTS: To explore how Tyr371 mutations affect Cbl’s properties, we used surface plasmon resonance to measure Cbl mutant binding affinities for E2 conjugated with ubiquitin (E2–Ub), small angle X-ray scattering studies to investigate Cbl mutant conformation in solution and focus formation assays to assay Cbl mutant transformation potential in cells. Cbl Tyr371 mutants enhance E2–Ub binding and cause Cbl to adopt extended conformations in solution. LHR flexibility, RING domain accessibility and transformation potential are associated with the extent of LHR-substrate-binding domain perturbation affected by the chemical nature of the mutation. More disruptive mutants like Cbl Y371D or Y371S are more extended and the RING domain is more accessible, whereas Cbl Y371F mimics native Cbl in solution. Correspondingly, the only Tyr371 mutants that potentiate transformation in cells are those that perturb the LHR-substrate-binding domain interaction. CONCLUSIONS: c-Cbl’s LHR mutations are only oncogenic when they disrupt the native state and fail to ubiquitinate PTKs. These findings provide new insights into how LHR mutations deregulate c-Cbl. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12915-016-0298-6) contains supplementary material, which is available to authorized users. BioMed Central 2016-09-08 /pmc/articles/PMC5015263/ /pubmed/27609087 http://dx.doi.org/10.1186/s12915-016-0298-6 Text en © Buetow et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Buetow, Lori
Tria, Giancarlo
Ahmed, Syed Feroj
Hock, Andreas
Dou, Hao
Sibbet, Gary J.
Svergun, Dmitri I.
Huang, Danny T.
Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation
title Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation
title_full Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation
title_fullStr Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation
title_full_unstemmed Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation
title_short Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation
title_sort casitas b-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015263/
https://www.ncbi.nlm.nih.gov/pubmed/27609087
http://dx.doi.org/10.1186/s12915-016-0298-6
work_keys_str_mv AT buetowlori casitasblineagelymphomalinkerhelixmutationsfoundinmyeloproliferativeneoplasmsaffectconformation
AT triagiancarlo casitasblineagelymphomalinkerhelixmutationsfoundinmyeloproliferativeneoplasmsaffectconformation
AT ahmedsyedferoj casitasblineagelymphomalinkerhelixmutationsfoundinmyeloproliferativeneoplasmsaffectconformation
AT hockandreas casitasblineagelymphomalinkerhelixmutationsfoundinmyeloproliferativeneoplasmsaffectconformation
AT douhao casitasblineagelymphomalinkerhelixmutationsfoundinmyeloproliferativeneoplasmsaffectconformation
AT sibbetgaryj casitasblineagelymphomalinkerhelixmutationsfoundinmyeloproliferativeneoplasmsaffectconformation
AT svergundmitrii casitasblineagelymphomalinkerhelixmutationsfoundinmyeloproliferativeneoplasmsaffectconformation
AT huangdannyt casitasblineagelymphomalinkerhelixmutationsfoundinmyeloproliferativeneoplasmsaffectconformation